Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia

Ralph Boccia, Imtiaz A. Malik, Vinay Raja, Stephen Kahanic, Randall Liu, Tom Lillie, Dianne Tomita, Billy Clowney, Peter T. Silberstein

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 μg) Q3W in patients with CIA. Eligible patients (≥18 years) were anemic (hemoglobin

Original languageEnglish
Pages (from-to)409-417
Number of pages9
JournalOncologist
Volume11
Issue number4
DOIs
StatePublished - Apr 2006

Fingerprint

Anemia
Drug Therapy
Therapeutics
Hemoglobins
Quality of Life
Darbepoetin alfa
Safety
Neoplasms

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Hematology

Cite this

Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. / Boccia, Ralph; Malik, Imtiaz A.; Raja, Vinay; Kahanic, Stephen; Liu, Randall; Lillie, Tom; Tomita, Dianne; Clowney, Billy; Silberstein, Peter T.

In: Oncologist, Vol. 11, No. 4, 04.2006, p. 409-417.

Research output: Contribution to journalArticle

Boccia, R, Malik, IA, Raja, V, Kahanic, S, Liu, R, Lillie, T, Tomita, D, Clowney, B & Silberstein, PT 2006, 'Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia', Oncologist, vol. 11, no. 4, pp. 409-417. https://doi.org/10.1634/theoncologist.11-4-409
Boccia, Ralph ; Malik, Imtiaz A. ; Raja, Vinay ; Kahanic, Stephen ; Liu, Randall ; Lillie, Tom ; Tomita, Dianne ; Clowney, Billy ; Silberstein, Peter T. / Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. In: Oncologist. 2006 ; Vol. 11, No. 4. pp. 409-417.
@article{10a7e518d7584ffdadb196d51f208645,
title = "Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia",
abstract = "Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 μg) Q3W in patients with CIA. Eligible patients (≥18 years) were anemic (hemoglobin",
author = "Ralph Boccia and Malik, {Imtiaz A.} and Vinay Raja and Stephen Kahanic and Randall Liu and Tom Lillie and Dianne Tomita and Billy Clowney and Silberstein, {Peter T.}",
year = "2006",
month = "4",
doi = "10.1634/theoncologist.11-4-409",
language = "English",
volume = "11",
pages = "409--417",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "4",

}

TY - JOUR

T1 - Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia

AU - Boccia, Ralph

AU - Malik, Imtiaz A.

AU - Raja, Vinay

AU - Kahanic, Stephen

AU - Liu, Randall

AU - Lillie, Tom

AU - Tomita, Dianne

AU - Clowney, Billy

AU - Silberstein, Peter T.

PY - 2006/4

Y1 - 2006/4

N2 - Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 μg) Q3W in patients with CIA. Eligible patients (≥18 years) were anemic (hemoglobin

AB - Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 μg) Q3W in patients with CIA. Eligible patients (≥18 years) were anemic (hemoglobin

UR - http://www.scopus.com/inward/record.url?scp=33645784831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645784831&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.11-4-409

DO - 10.1634/theoncologist.11-4-409

M3 - Article

VL - 11

SP - 409

EP - 417

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 4

ER -